A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
Clinical trial NCT07073547 · RECRUITING
Trial details
- NCT number
- NCT07073547
- Sponsor
- AstraZeneca
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2025-07-31
- Primary completion
- 2028-05-26
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.